人工智能在PSMA PET/CT中的应用
The Application of Artificial Intelligence in PSMA PET/CT
DOI: 10.12677/ACM.2024.141215, PDF,   
作者: 张皓哲*：山东第一医科大学第二附属医院泌尿外科，山东 泰安；山东第一医科大学(山东省医学科学院)研究生院，山东 济南；曹 敏*：山东第一医科大学(山东省医学科学院)研究生院，山东 济南；冀 明, 刘洪年#：山东第一医科大学第二附属医院泌尿外科，山东 泰安
关键词: 人工智能；前列腺特异性膜抗原；正电子发射体层成像；前列腺癌；Artificial Intelligence； Prostate-Specific Membrane Antigen； Positron Emission Tomography； Prostate Cancer
摘要: 前列腺特异性膜抗原(Prostate-Specific Membrane Antigen, PSMA)正电子发射断层扫描(Positron Emission Tomography, PET)/计算机断层扫描(Computed Tomography, CT)已成为前列腺癌重要的成像技术。随着研究和应用的深入拓展，人工智能(Artificial Intelligence, AI)开始应用于PSMA PET/CT。本文分析了人工智能在PSMA PET/CT前列腺癌成像中的发展和应用。然后综合介绍了目前AI技术在前列腺病灶检测、分类、分期、治疗及预后等方面的应用现状。大量研究已证明，AI技术在PSMA PET/CT方面取得了显著的成果，但仍面临一些挑战。未来，AI技术有望为医生提供更准确和个体化的前列腺癌诊断和治疗决策支持。
Abstract: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has emerged as an essential imaging modality for prostate cancer. With the advancement and application of research, the integration of artificial intelligence (AI) into PSMA PET/CT imaging has begun. This article critically examines the development and utilization of AI in PSMA PET/CT imaging for prostate cancer. Additionally, it provides a comprehensive overview of the current ap-plication status of AI technology in detecting, classifying, staging, treating, and prognosticating prostate lesions. A number of investigations have showcased the remarkable achievements of AI technology in the realm of PSMA PET/CT, albeit still encountering certain challenges. In the future, AI technology is expected to facilitate more precise and individualized support for the diagnosis and treatment decision-making of prostate cancer.
文章引用：张皓哲, 曹敏, 冀明, 刘洪年. 人工智能在PSMA PET/CT中的应用[J]. 临床医学进展, 2024, 14(1): 1501-1507. https://doi.org/10.12677/ACM.2024.141215

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Qiu, H., Cao, S. and Xu, R. (2021) Cancer Incidence, Mortality, and Bur-den in China: A Time-Trend Analysis and Comparison with the United States and United Kingdom Based on the Global Epidemiological Data Released in 2020. Cancer Communications (London), 41, 1037-1048. [Google Scholar] [CrossRef] [PubMed]
[3] Parker, C., Castro, E., Fizazi, K., et al. (2020) Prostate Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 31, 1119-1134. [Google Scholar] [CrossRef] [PubMed]
[4] Kuten, J., Kesler, M. and Even-Sapir, E. (2021) The Role of PSMA PET/CT in Imaging Prostate Cancer. Harefuah, 160, 455-461.
[5] Klingenberg, S., Jochumsen, M.R., Ulhøi, B.P., et al. (2021) 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer. Journal of Nuclear Medicine, 62, 214-220. [Google Scholar] [CrossRef] [PubMed]
[6] Maurer, T., Eiber, M., Schwaiger, M., et al. (2016) Current Use of PSMA-PET in Prostate Cancer Management. Nature Reviews Urology, 13, 226-235. [Google Scholar] [CrossRef] [PubMed]
[7] Bagguley, D., Ong, S., Buteau, J.P., et al. (2021) Role of PSMA PET/CT Imaging in the Diagnosis, Staging and Restaging of Prostate Cancer. Future Oncology, 17, 2225-2241. [Google Scholar] [CrossRef] [PubMed]
[8] Barbosa, Á.R.G., Amaral, B.S., Lourenço, D.B., et al. (2022) Accura-cy of 68Ga-PSMA PET-CT and PET-MRI in Lymph Node Staging for Localized Prostate Cancer. Einstein (Sao Paulo), 20, eAO6599. [Google Scholar] [CrossRef] 
[9] Pozdnyakov, A., Kulanthaivelu, R., Bauman, G., et al. (2023) The Impact of PSMA PET on the Treatment and Outcomes of Men with Biochemical Recurrence of Prostate Cancer: A Systematic Review and Meta-Analysis. Prostate Cancer and Prostatic Diseases, 26, 240-248. [Google Scholar] [CrossRef] [PubMed]
[10] Rüschoff, J.H., Ferraro, D.A., Muehlematter, U.J., et al. (2021) What’s behind 68Ga-PSMA-11 Uptake in Primary Prostate Cancer PET? Investigation of Histopathological Parameters and Immunohistochemical PSMA Expression Patterns. European Journal of Nuclear Medicine and Molecular Imaging, 48, 4042-4053. [Google Scholar] [CrossRef] [PubMed]
[11] Eiber, M., Weirich, G., Holzapfel, K., et al. (2016) Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. European Urology, 70, 829-836. [Google Scholar] [CrossRef] [PubMed]
[12] Peng, L., Li, J., Meng, C., et al. (2020) Can 68Ga-Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Provide an Ac-curate Lymph Node Staging for Patients with Medium/High Risk Prostate Cancer? A Diagnostic Meta-Analysis. Radia-tion Oncology, 15, Article No. 227. [Google Scholar] [CrossRef] [PubMed]
[13] Qiu, D.X., Li, J., Zhang, J.W., et al. (2022) Dual-Tracer PET/CT-Targeted, mpMRI-Targeted, Systematic Biopsy, and Combined Biopsy for the Diagnosis of Prostate Cancer: A Pilot Study. European Journal of Nuclear Medicine and Molecular Imaging, 49, 2821-2832. [Google Scholar] [CrossRef] [PubMed]
[14] Hoffmann, M.A., von Eyben, F.E., Fischer, N., et al. (2022) Comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse. Cancers (Basel), 14, Article No. 1479. [Google Scholar] [CrossRef] [PubMed]
[15] Seetharaman, A., Bhattacharya, I., Chen, L.C., et al. (2021) Auto-mated Detection of Aggressive and Indolent Prostate Cancer on Magnetic Resonance Imaging. Medical Physics, 48, 2960-2972. [Google Scholar] [CrossRef] [PubMed]
[16] Xie, W., Reder, N.P., Koyuncu, C., et al. (2022) Prostate Can-cer Risk Stratification via Nondestructive 3D Pathology with Deep Learning-Assisted Gland Analysis. Cancer Research, 82, 334-345. [Google Scholar] [CrossRef] 
[17] Vergani, V., Razavi, R., Puyol-Antón, E., et al. (2021) Deep Learning for Classification and Selection of Cine CMR Images to Achieve Fully Automated Quality-Controlled CMR Analysis from Scanner to Report. Frontiers in Cardiovascular Medicine, 8, Article ID: 742640. [Google Scholar] [CrossRef] [PubMed]
[18] Bravi, C.A., Paciotti, M., Sarchi, L., et al. (2022) Robot-Assisted Radical Prostatectomy with the Novel Hugo Robotic System: Initial Experience and Optimal Surgical Set-Up at a Tertiary Referral Robotic Center. European Urology, 82, 233-237. [Google Scholar] [CrossRef] [PubMed]
[19] Spohn, S.K.B., Kramer, M., Kiefer, S., et al. (2020) Comparison of Manual and Semi-Automatic [18F]PSMA-1007 PET Based Contouring Techniques for Intraprostatic Tumor Delineation in Patients with Primary Prostate Cancer and Validation with Histopathology as Standard of Reference. Frontiers in Oncology, 10, Article ID: 600690. [Google Scholar] [CrossRef] [PubMed]
[20] Yi, Z., Hu, S., Lin, X., et al. (2022) Machine Learning-Based Pre-diction of Invisible Intraprostatic Prostate Cancer Lesions on 68Ga-PSMA-11 PET/CT in Patients with Primary Prostate Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 49, 1523-1534. [Google Scholar] [CrossRef] [PubMed]
[21] Hinzpeter, R., Baumann, L., Guggenberger, R., et al. (2022) Ra-diomics for Detecting Prostate Cancer Bone Metastases Invisible in CT: A Proof-of-Concept Study. European Radiology, 32, 1823-1832. [Google Scholar] [CrossRef] [PubMed]
[22] Zhao, Y., Gafita, A., Vollnberg, B., et al. (2020) Deep Neural Network for Automatic Characterization of Lesions on 68Ga-PSMA-11 PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 47, 603-613. [Google Scholar] [CrossRef] [PubMed]
[23] Hartenstein, A., Lübbe, F., Baur, A.D.J., et al. (2020) Prostate Cancer Nodal Staging: Using Deep Learning to Predict 68Ga-PSMA-Positivity from CT Imaging Alone. Scientific Re-ports, 10, Article No. 3398. [Google Scholar] [CrossRef] [PubMed]
[24] Holzschuh, J.C., Mix, M., Ruf, J., et al. (2023) Deep Learning based Automated Delineation of the Intraprostatic Gross Tumour Volume in PSMA-PET for Patients with Primary Prostate Cancer. Radiotherapy and Oncology, 2023, Article ID: 109774. [Google Scholar] [CrossRef] [PubMed]
[25] Spohn, S.K.B., Schmidt-Hegemann, N.S., Ruf, J., et al. (2023) Development of PSMA-PET-Guided CT-Based Radiomic Signature to Predict Biochemical Recurrence after Salvage Ra-diotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 50, 2537-2547. [Google Scholar] [CrossRef] [PubMed]
[26] Kendrick, J., Francis, R.J., Hassan, G.M., et al. (2022) Fully Automatic Prognostic Biomarker Extraction from Metastatic Prostate Lesion Segmentations in Whole-Body [68Ga]Ga-PSMA-11 PET/CT Images. European Journal of Nuclear Medicine and Molecular Imaging, 50, 67-79. [Google Scholar] [CrossRef] [PubMed]
[27] Cysouw, M.C.F., Jansen, B.H.E., van de Brug, T., et al. (2021) Machine Learning-Based Analysis of [18F]DCFPyL PET Radiomics for Risk Stratification in Primary Prostate Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48, 340-349. [Google Scholar] [CrossRef] [PubMed]
[28] Zang, S., Ai, S., Yang, R., et al. (2022) Development and Vali-dation of 68Ga-PSMA-11 PET/CT-Based Radiomics Model to Detect Primary Prostate Cancer. EJNMMI Research, 12, Article No. 63. [Google Scholar] [CrossRef] [PubMed]
[29] Erle, A., Moazemi, S., Lütje, S., et al. (2021) Evaluating a Ma-chine Learning Tool for the Classification of Pathological Uptake in Whole-Body PSMA-PET-CT Scans. Tomography, 7, 301-312. [Google Scholar] [CrossRef] [PubMed]
[30] Leung, K.H., Rowe, S.P., Leal, J.P., et al. (2022) Deep Learning and Radiomics Framework for PSMA-RADS Classification of Prostate Cancer on PSMA PET. EJNMMI Research, 12, Article No. 76. [Google Scholar] [CrossRef] [PubMed]
[31] Gafita, A., Rauscher, I., Fendler, W.P., et al. (2022) Measuring Response in Metastatic Castration-Resistant Prostate Cancer Using PSMA PET/CT: Comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 Criteria. European Journal of Nuclear Medicine and Molecular Imaging, 49, 4271-4281. [Google Scholar] [CrossRef] [PubMed]
[32] Ferdinandus, J., Violet, J., Sandhu, S., et al. (2020) Prognostic Biomarkers in Men with Metastatic Castration-Resistant Prostate Cancer Receiving [177Lu]-PSMA-617. European Jour-nal of Nuclear Medicine and Molecular Imaging, 47, 2322-2327. [Google Scholar] [CrossRef] [PubMed]
[33] Seifert, R., Herrmann, K., Kleesiek, J., et al. (2020) Semiauto-matically Quantified Tumor Volume Using (68)Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Ad-vanced Prostate Cancer. Journal of Nuclear Medicine, 61, 1786-1792. [Google Scholar] [CrossRef] [PubMed]
[34] Sartor, O., de Bono, J., Chi, K.N., et al. (2021) Luteti-um-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. The New England Journal of Medicine, 385, 1091-1103. [Google Scholar] [CrossRef] 
[35] Capobianco, N., Sibille, L., Chantadisai, M., et al. (2022) Whole-Body Uptake Classification and Prostate Cancer Staging in 68Ga-PSMA-11 PET/CT Using Dual-Tracer Learning. European Journal of Nuclear Medicine and Molecular Imaging, 49, 517-526. [Google Scholar] [CrossRef] [PubMed]
[36] Ghezzo, S., Mapelli, P., Bezzi, C., et al. (2023) Role of [68Ga]Ga-PSMA-11 PET Radiomics to Predict Post-Surgical ISUP Grade in Primary Prostate Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 50, 2548-2560. [Google Scholar] [CrossRef] [PubMed]
[37] Yao, F., Bian, S., Zhu, D., et al. (2022) Machine Learning-Based Radiomics for Multiple Primary Prostate Cancer Biological Characteristics Prediction with 18F-PSMA-1007 PET: Com-parison among Different Volume Segmentation Thresholds. La Radiologia Medica, 127, 1170-1178. [Google Scholar] [CrossRef] [PubMed]
[38] Tran, V.T., Tu, S.J. and Tseng, J.R. (2022) 68Ga-PSMA-11 PET/CT Features Extracted from Different Radiomic Zones Predict Response to Androgen Deprivation Therapy in Pa-tients with Advanced Prostate Cancer. Cancers (Basel), 14, Article No. 4838. [Google Scholar] [CrossRef] [PubMed]
[39] Moazemi, S., Erle, A., Khurshid, Z., et al. (2021) Decision-Support for Treatment with 177Lu-PSMA: Machine Learning Predicts Response with High Accuracy Based on PSMA-PET/CT and Clinical Parameters. Annals of Translational Medicine, 9, Article No. 818. [Google Scholar] [CrossRef] [PubMed]
[40] Moazemi, S., Erle, A., Lütje, S., et al. (2021) Estimating the Potential of Radiomics Features and Radiomics Signature from Pretherapeutic PSMA-PET-CT Scans and Clinical Data for Prediction of Overall Survival When Treated with 177Lu-PSMA. Diagnostics (Basel), 11, Article No. 186. [Google Scholar] [CrossRef] [PubMed]
[41] Kelk, E., Ruuge, P., Rohtla, K., et al. (2021) Radiomics Analysis for 177Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer—A Model Based on Clinical Example. Life (Basel), 11, Article No. 170. [Google Scholar] [CrossRef] [PubMed]
[42] Castaldo, R., Cavaliere, C., Soricelli, A., et al. (2021) Radiomic and Ge-nomic Machine Learning Method Performance for Prostate Cancer Diagnosis: Systematic Literature Review. Journal of Medical Internet Research, 23, e22394. [Google Scholar] [CrossRef] [PubMed]
[43] Panunzio, A., Tafuri, A., Princiotta, A., et al. (2021) Omics in Urology: An Overview on Concepts, Current Status and Future Perspectives. Urologia, 88, 270-279. [Google Scholar] [CrossRef] [PubMed]

为你推荐